A 58-year-old man with a 10-year history of rheumatoid arthritis presents with nephrotic syndrome and hepatosplenomegaly. Renal biopsy shows amyloid deposition. Which finding would most reliably distinguish his amyloidosis from a patient with multiple myeloma presenting with similar renal amyloidosis?

Question

Accepted Answer

D. Positive staining for serum amyloid A protein rather than immunoglobulin light chains on immunohistochemistry. ## AA vs AL Amyloidosis in Renal Disease

### Clinical Scenario Analysis

**Key Point:** This patient has secondary (AA) amyloidosis due to chronic inflammatory arthritis, not primary (AL) amyloidosis from plasma cell dyscrasia. The distinguishing feature is the **protein composition** of the amyloid, not the clinical presentation or bone marrow findings.

### Pathophysiology Comparison

| Parameter | AA Amyloidosis (This Patient) | AL Amyloidosis (Multiple Myeloma) |
|-----------|---|---|
| **Trigger** | Chronic inflammation (RA, TB, osteomyelitis) | Plasma cell dyscrasia (monoclonal) |
| **Amyloid protein** | Serum amyloid A (hepatic acute-phase reactant) | Immunoglobulin light chains (κ or λ) |
| **Bone marrow** | Normal or reactive plasmacytosis | Clonal plasma cell infiltration (>10%) |
| **Serum protein electrophoresis** | Normal or polyclonal pattern | Monoclonal spike (M-protein) |
| **Immunohistochemistry** | AA protein positive; light chains negative | κ or λ light chain positive; AA negative |
| **Organ involvement** | Kidneys >> liver, spleen | Heart, nerves, kidneys |

### Why Immunohistochemistry is the Discriminator

**High-Yield:** Immunohistochemistry (or immunofluorescence) of the renal biopsy showing **AA protein positivity** definitively identifies secondary amyloidosis from chronic inflammation. In contrast, AL amyloidosis shows light chain (κ or λ) positivity.

**Clinical Pearl:** A patient with RA and amyloidosis almost always has AA amyloidosis (secondary to chronic inflammation), not AL. However, a patient with multiple myeloma and amyloidosis has AL amyloidosis (from monoclonal light chains). The **tissue protein composition** is the gold standard discriminator.

**Mnemonic:** **AA = Arthritis/Acute-phase**; **AL = Amyloid Light-chain**.

### Why Other Options Fail as Discriminators

**Warning:** A monoclonal spike on SPEP can occur in both AL amyloidosis (from the plasma cell clone) and in some cases of AA amyloidosis (as an incidental finding or from a separate monoclonal gammopathy). It is not a reliable discriminator.

- **Glomerular vs. vascular deposition:** Both AL and AA can deposit in glomeruli; this is not a consistent discriminator.
- **Bone marrow findings:** While AL typically shows clonal plasma cells and AA shows reactive changes, bone marrow examination is not as direct or reliable as tissue immunohistochemistry. Additionally, some patients with AA may have reactive plasmacytosis that could be misinterpreted.

Answer

A. Absence of a clonal plasma cell population on bone marrow examination

Answer

B. Predominant amyloid deposition in the glomeruli rather than blood vessel walls

Answer

C. Presence of a monoclonal spike on serum protein electrophoresis

Explanation

AA vs AL Amyloidosis in Renal Disease

Clinical Scenario Analysis

Pathophysiology Comparison

Why Immunohistochemistry is the Discriminator

Why Other Options Fail as Discriminators

Practice similar questions

Join our NEET PG community

Parameter	AA Amyloidosis (This Patient)	AL Amyloidosis (Multiple Myeloma)
Trigger	Chronic inflammation (RA, TB, osteomyelitis)	Plasma cell dyscrasia (monoclonal)
Amyloid protein	Serum amyloid A (hepatic acute-phase reactant)	Immunoglobulin light chains (κ or λ)
Bone marrow	Normal or reactive plasmacytosis	Clonal plasma cell infiltration (>10%)
Serum protein electrophoresis	Normal or polyclonal pattern	Monoclonal spike (M-protein)
Immunohistochemistry	AA protein positive; light chains negative	κ or λ light chain positive; AA negative
Organ involvement	Kidneys >> liver, spleen	Heart, nerves, kidneys